PMID- 38519329
OWN - NLM
STAT- Publisher
LR  - 20240322
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
DP  - 2024 Feb 12
TI  - Recent Developments in Convenience of Administration of the Anti-CD38 Antibody 
      Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With 
      Multiple Myeloma.
LID - S2152-2650(24)00063-6 [pii]
LID - 10.1016/j.clml.2024.02.004 [doi]
AB  - Isatuximab-based combinations are among the accepted standard-of-care regimens 
      for early-line treatment of patients with relapsed/refractory multiple myeloma 
      (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further 
      study findings have shown benefit with Isa-based combinations in patients with 
      newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. 
      Isa is currently approved in various countries for intravenous (IV) 
      administration in patients with RRMM. A more convenient route of administration, 
      such as subcutaneous (SC) injection, and faster IV infusion may substantially 
      increase convenience of treatment. In this review, we outline evidence emerging 
      from clinical trials that shows increasing clinical applicability of Isa across 
      the MM therapeutic spectrum. We then review recent study results demonstrating 
      that new treatment modalities, either SC Isa administration via an on-body 
      delivery system (OBDS) or fast, 30-minute, fixed-volume IV infusion, are safe and 
      effective, and enhance convenience of treatment with Isa for MM patients and 
      healthcare providers. In the recently reported Phase 1b study, the safety profile 
      and efficacy of Isa administered SC plus pomalidomide-dexamethasone were 
      comparable to those observed with Isa administered IV plus 
      pomalidomide-dexamethasone in the control arm and in the ICARIA-MM trial. 
      Analysis of patient-reported outcomes indicated patient confidence in SC Isa 
      administration and satisfaction with treatment delivery by OBDS. These findings 
      point to SC administration as the preferred route for future treatment with 
      Isa-based combinations, as well as to the use of fast, 30-minute IV infusions in 
      settings where SC administration of Isa might not be available.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Quach, Hang
AU  - Quach H
AD  - Clinical Haematology Service, St Vincent's Hospital Melbourne, University of 
      Melbourne, Vic, Australia. Electronic address: hang.quach@svha.org.au.
FAU - Parmar, Gurdeep
AU  - Parmar G
AD  - Illawarra Cancer Care Centre, Wollongong, NSW, Australia.
FAU - Mateos, Maria-Victoria
AU  - Mateos MV
AD  - University Hospital of Salamanca and Cancer Research Center (IBMCC-CSICUSAL), 
      Salamanca, Spain.
FAU - Ailawadhi, Sikander
AU  - Ailawadhi S
AD  - Division of Hematology/Oncology, Mayo Clinic Florida, Jacksonville, FL.
FAU - Leleu, Xavier
AU  - Leleu X
AD  - Service d'Hematologie et Therapie Cellulaire, CHU and CIC Inserm 1402, Poitiers 
      Cedex, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240212
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
OTO - NOTNLM
OT  - Infusion pump
OT  - Newly diagnosed multiple myeloma
OT  - OBDS
OT  - on-body delivery system, Relapsed/refractory multiple myeloma
EDAT- 2024/03/23 05:42
MHDA- 2024/03/23 05:42
CRDT- 2024/03/22 23:03
PHST- 2024/01/05 00:00 [received]
PHST- 2024/02/08 00:00 [accepted]
PHST- 2024/03/23 05:42 [medline]
PHST- 2024/03/23 05:42 [pubmed]
PHST- 2024/03/22 23:03 [entrez]
AID - S2152-2650(24)00063-6 [pii]
AID - 10.1016/j.clml.2024.02.004 [doi]
PST - aheadofprint
SO  - Clin Lymphoma Myeloma Leuk. 2024 Feb 12:S2152-2650(24)00063-6. doi: 
      10.1016/j.clml.2024.02.004.